Double-blind randomized controlled trial of rifaximin for persistent symptoms in patients with celiac disease. (Q50519233)

14 March 2018

title

Double-blind randomized controlled trial of rifaximin for persistent symptoms in patients with celiac disease. (English)

1 reference

14 March 2018

author name string

Matthew S Chang

1

1 reference

14 March 2018

Maria T Minaya

2

1 reference

14 March 2018

Jianfeng Cheng

3

1 reference

14 March 2018

Bradley A Connor

4

1 reference

14 March 2018

Suzanne K Lewis

5

1 reference

14 March 2018

Peter H R Green

6

1 reference

14 March 2018

publication date

7 June 2011

1 reference

14 March 2018

Digestive Diseases and Sciences

published in

1 reference

14 March 2018

volume

56

1 reference

14 March 2018

issue

10

1 reference

14 March 2018

page(s)

2939-2946

1 reference

14 March 2018

https://scigraph.springernature.com/pub.10.1007/s10620-011-1719-6

exact match

0 references

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1719-6

Review article: management of patients with non-responsive coeliac disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1719-6

Prevalence of small intestine bacterial overgrowth diagnosed by quantitative culture of intestinal aspirate in celiac disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1719-6

High prevalence of small intestinal bacterial overgrowth in celiac patients with persistence of gastrointestinal symptoms after gluten withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1719-6

Etiology of nonresponsive celiac disease: results of a systematic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1719-6

Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1719-6

Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1719-6

A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1719-6

Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1719-6

Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-D-xylose and healthy controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1719-6

Gastrointestinal symptoms rating scale in coeliac disease patients on wheat starch-based gluten-free diets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1719-6

Quality of life of adult coeliac patients treated for 10 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1719-6

Dietary compliance and health-related quality of life in patients with coeliac disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1719-6

Rifaximin therapy for patients with irritable bowel syndrome without constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1719-6

Etiologies and predictors of diagnosis in nonresponsive celiac disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1719-6

Psychosocial Factors Are More Important Than Disease Activity in Determining Gastrointestinal Symptoms and Health Status in Adults at a Celiac Disease Referral Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1719-6

Small intestinal bacterial overgrowth: diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1719-6

A systematic review of diagnostic tests for small intestinal bacterial overgrowth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1719-6

Refractory celiac disease

21 January 2018

1 reference

12 December 2020

Gastroesophageal Reflux Symptoms in Patients With Celiac Disease and the Effects of a Gluten-Free Diet

1 reference

12 December 2020

Rifaximin, a peculiar rifamycin derivative: established and potential clinical use outside the gastrointestinal tract

1 reference

12 December 2020

Fasting breath hydrogen in celiac disease.

1 reference

12 December 2020

Jejunal bacterial flora in chronic small bowel disease. I. Celiac disease. II. Regional enteritis

1 reference

12 December 2020

Small intestinal bacterial overgrowth

1 reference

12 December 2020

The prevalence and causes of chronic diarrhea in patients with celiac sprue treated with a gluten-free diet

1 reference

12 December 2020

Gluten-free diet and quality of life in patients with screen-detected celiac disease.

1 reference

12 December 2020

Review of rifaximin as treatment for SIBO and IBS

1 reference

12 December 2020

High dosage rifaximin for the treatment of small intestinal bacterial overgrowth

1 reference

12 December 2020

High rate of gastrointestinal symptoms in celiac patients living on a gluten-free diet: controlled study

1 reference

12 December 2020

Partially responsive celiac disease resulting from small intestinal bacterial overgrowth and lactose intolerance

1 reference

12 December 2020

Effect of antibiotic therapy on gluten-sensitive enteropathy

1 reference

12 December 2020

GSRS--a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease

1 reference

12 December 2020

Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study

1 reference

12 December 2020

Small intestinal bacterial overgrowth in North Indian patients with celiac disease.

1 reference

12 December 2020

The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing

1 reference

12 December 2020

10.1007/S10620-011-1719-6

Identifiers

DOI

1 reference

14 March 2018

PubMed ID

21647654

1 reference

14 March 2018